Gordon Thomson, Principal Clinical Pharmacist, NHS Tayside discusses how they implemented PharmacyView, reducing their time spent on administrative tasks, enabling the more efficient deployment of staff resource and how they can now more easily identify priority patients on high risk drugs.
How the TGA uses implant registry data: Experience with the Australian Orthop...TGA Australia
The recent TGA review of devices has foreshadowed a much greater role for registries in monitoring the long and intermediate term safety of new devices. This presentation provides an example of an established device registry to explore issues such as governance, funding, record linkage, reporting etc.
What you can do with Generic HIS
Increase your revenues and profits
Measure and optimize to create better strategies and tactics using standard MIS and standard reports
Increase Brand Reputation
Provide a wow patient experience and get more referrals through your happy patients
Optimize Productivity
Leverage automation and Data flow across departments to ensure optimum productivity levels for your team
Reduce Inventory Leakages
Maximize your inventory control to ensure that you have a tight control and optimum reorder levels
Increase Visibility
Use Audit Trail to track everything in your hospital. Track your user’s actions and movement using it.
Compliance history as a driver for reinspection frequenciesTGA Australia
This presentation provides an update of changes the TGA have made to the product / process risk matrix and reinspection frequencies for medicines and blood, tissue and cellular therapies.
Presentation: Transparency initiatives and the TGATGA Australia
This presentation provides an overview of the web publication of Australian Public Assessment Reports (AusPARs), including findings of the recent survey.
How the TGA uses implant registry data: Experience with the Australian Orthop...TGA Australia
The recent TGA review of devices has foreshadowed a much greater role for registries in monitoring the long and intermediate term safety of new devices. This presentation provides an example of an established device registry to explore issues such as governance, funding, record linkage, reporting etc.
What you can do with Generic HIS
Increase your revenues and profits
Measure and optimize to create better strategies and tactics using standard MIS and standard reports
Increase Brand Reputation
Provide a wow patient experience and get more referrals through your happy patients
Optimize Productivity
Leverage automation and Data flow across departments to ensure optimum productivity levels for your team
Reduce Inventory Leakages
Maximize your inventory control to ensure that you have a tight control and optimum reorder levels
Increase Visibility
Use Audit Trail to track everything in your hospital. Track your user’s actions and movement using it.
Compliance history as a driver for reinspection frequenciesTGA Australia
This presentation provides an update of changes the TGA have made to the product / process risk matrix and reinspection frequencies for medicines and blood, tissue and cellular therapies.
Presentation: Transparency initiatives and the TGATGA Australia
This presentation provides an overview of the web publication of Australian Public Assessment Reports (AusPARs), including findings of the recent survey.
CPOE - Computerized Physician Order EntryKristie Brown
CPOE is now a requirement for ARRA. This talks about the items that need to be focused on for CPOE implementations. It is geared towards MEDITECH, but the ideas can be used for any EMR system. Check out the excelhcg youtube channel for a video presentation.
A presentation at "Linked Data in Sweden - Linköping University" showing the benefit of using WHODrug as linked data. Should this work be continued or is there no business value in it?
Presentation: Risk minimisation in the Australian contextTGA Australia
This presentation describes Risk Minimisation including general principles and the tools available for the development of Risk Minimisation Plans (RMPs)
TGA presentation: Codeine Industry Forum - Regulatory options for up-schedulingTGA Australia
To provide sponsors of OTC codeine products with information on how to submit an application to change the class of their product from OTC to prescription medicine
Premarket Clinical Evaluation under the EU MDR proposalAnnet Visscher
Premarket Clinical Evaluation under the current version of the European Medical Device Regulation proposal. What are key elements and how does it impact the clinical evidence needs?
Medical Devices Postmarket Surveillance in Europe updatedAnnet Visscher
Medical Device Postmarket Surveillance and Clinical Follow-up under the proposed European Medical Device Regulation updated according to the latest amendments.
Clinical evaluation report cer in a more stringent regulatory- Pepgra HealthcarePEPGRA Healthcare
European regulatory framework has established rules that govern the development, manufacturing, and marketing of medical devices in the European market. Both European and non-European medical device manufacturer’s fall under the purview of the regulatory framework, which is established to
provide condence to the clinicians and the patients that the medical devices and the implantable devices used in the region have been validated for their potential benets and certied as safe for usage.
Presentation: IGDRP - Mission, scope, how it worksTGA Australia
This presentation provides an overview of the International Generic Drug Regulators Programme (IGDRP), its conception including its mission and objectives, and the activities of its various working group and its future.
CPOE - Computerized Physician Order EntryKristie Brown
CPOE is now a requirement for ARRA. This talks about the items that need to be focused on for CPOE implementations. It is geared towards MEDITECH, but the ideas can be used for any EMR system. Check out the excelhcg youtube channel for a video presentation.
A presentation at "Linked Data in Sweden - Linköping University" showing the benefit of using WHODrug as linked data. Should this work be continued or is there no business value in it?
Presentation: Risk minimisation in the Australian contextTGA Australia
This presentation describes Risk Minimisation including general principles and the tools available for the development of Risk Minimisation Plans (RMPs)
TGA presentation: Codeine Industry Forum - Regulatory options for up-schedulingTGA Australia
To provide sponsors of OTC codeine products with information on how to submit an application to change the class of their product from OTC to prescription medicine
Premarket Clinical Evaluation under the EU MDR proposalAnnet Visscher
Premarket Clinical Evaluation under the current version of the European Medical Device Regulation proposal. What are key elements and how does it impact the clinical evidence needs?
Medical Devices Postmarket Surveillance in Europe updatedAnnet Visscher
Medical Device Postmarket Surveillance and Clinical Follow-up under the proposed European Medical Device Regulation updated according to the latest amendments.
Clinical evaluation report cer in a more stringent regulatory- Pepgra HealthcarePEPGRA Healthcare
European regulatory framework has established rules that govern the development, manufacturing, and marketing of medical devices in the European market. Both European and non-European medical device manufacturer’s fall under the purview of the regulatory framework, which is established to
provide condence to the clinicians and the patients that the medical devices and the implantable devices used in the region have been validated for their potential benets and certied as safe for usage.
Presentation: IGDRP - Mission, scope, how it worksTGA Australia
This presentation provides an overview of the International Generic Drug Regulators Programme (IGDRP), its conception including its mission and objectives, and the activities of its various working group and its future.
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
MedTech clinical data collection problems have been found throughout our ten years of work with over 250 medical device studies from across the globe. We keep running across these seven hazards while working in the MedTech business and clinical operations.
Hospital Management and Inventory Control Solution for Public Hospitals in De...Mamoon Ismail Khalid
Historic underinvestment in public health has left Ecuador
with one of the most inefficient health systems in the region.
The Problem
Little info sharing
The lack of interoperable
systems and records
management contributes to a
lack of understanding of public
health needs leads to
treatments that don't really
address overall health issues
Bureaucracy
Public health employees are
engaged in redundant
administrative tasks that divert
resources from patient care and
clog system
PAPER RECORDING OF INFORMATION
Medical assistants need to manually fill in 5
different records (1 per prescription), they
first do it in paper and then typed it in the
computer since the Wi-Fi is not reliable.
Excessive waits
Lead times for getting
appointments in and long
check in processes lead to
patients abandoning
preventative care that could
save money and improve
patient outcomes
Most people we surveyed
complained about lead time. It
becomes even more
aggravating when it’s an
emergency.
Abuse and waste
Inability to track prescriptions
and inventory offer opportunity
for abuse that undermines the
system's overall quality
The result:
Costly, Inefficient
and non-citizen
centric public
healthcare system
The result:
Costly, Inefficient
and non-citizen
centric public
healthcare system
Here is our corporate profile, you will find information about all our solutions for vaccines clinical trials and also patient's programs. We have a variety of mobile and web apps that have been developed to enhance and improve your results in any clinical trial or patient care system.
The Top 5 Ancillary Services For Urology PracticesClark Love
Reduction in Medicare contract payments and decreased physician reimbursement from insurers are causing decreased physician salaries, medical profits and general revenue. This is driving the desire for urology practices to add ancillary services - and this is a good thing for patients.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
2. Introduction – Andrew Grant, Nugensis
PharmacyView Implementation, Gordon Thomson,
NHS Tayside
PharmacyView Demo - Andrew Grant, Nugensis
PharmacyView Reporting Dashboard - Andrew Grant,
Nugensis
Questions for the Panel
TODAY’S AGENDA
3. Gordon Thomson,
Head of Clinical Pharmacy Development
NHS Tayside
IMPLEMENTING
PHARMACYVIEW
A tool for clinical teams, team leaders and
the organisation
4. PHARMACYVIEW
Nugensis product – part of a suite of
tools linked to the eWhiteboard
programme
Data populated from Topas
(Trakcare)
5 additional fields to be populated
by Pharmacy staff to record activity
Data moves with the patient within
NHS Tayside hospitals
5. Pharmacy Technician
Identify new admissions
8am Spt/Snr PhTech Access TOPAS, create report for ward
set, print, highlight new admissions since last working day
(8am previous day)
Check eDD for discharges
Spt/Snr Ph Tech access eDD to identify list if discharge
workload in the morning signed off by doctor
Approx 15 Minutes
(Per Patient)
Give TOPAS sheets to Ph Techs
Spt/Snr Ph Tech gives endorsed TOPAS sheets to Ph Tech
covering ward and highlights discharges on eDD.
Pharmacy Technician transits to ward
Check data on TOPAS sheet with Ward
Data
Compare data on whiteboard/WardView and annotate TOPAS
sheets with bay/bed information.
5
Minutes
Approx 20 Minutes
(Per Patient)
Are there
eDD’s on the
system?
Yes No
POD Check New
Patients
Working from TOPAS sheets, TPAR
& PODs assess the suitability of
PODs and communicate problems
/ discrepancies to the ward
pharmacist
5
Minutes
Ward Clinical Pharmacist
20-30
Minutes
Identify and plan workload for ward 3
• Filter patients with first green tick on eDD column.
•Filter patients with no triage category documented.
•Filter patients due for review today.
Filter
PharmacyView
Are there eDD’s
(first green tick)
(Not part of testing
as IT issues with link)
Transit to ward
Yes
No
Sign off eDD
(Not part of testing as IT
issues with link)
Filter
PharmacyView
Are there patients
with no triage
category
Yes
NoClinically Review Patients
Med Rec, TPAR screen, Bloods
Update PharmacyView column.
Filter PharmacyView by
Review Date
Review all patients due
for review today.
Access to Clinical Portal and eDD and
other IT systems accessed via intranet
Confirm if new Patient(s) screened from AMU
•Manual examination of medical notes, update Pharmacy View if required
25Minutes
10
Minutes
10 Minutes
(Per Patient)
20
Minutes
(Per
Ptient)
10Minutes(Per
Patient)
PHARMACYVIEW PROJECT – Where is Agnes?DischargePatientJourney
Admission Process Mapping Exercise – Current Technical and Clinical Practice
6.
7.
8. PHARMACYVIEW PROJECT – Where is Agnes?
Process Mapping Exercise – Pharmacy View Testing
Pharmacy Technician Ward Clinical Pharmacist
Identify and plan workload for ward 3
•Filter patients with red cross in Pod Check column.
•Filter patients with first green tick eDD column.
(Not part of testing as IT issues with link)
Open PharmacyView on desktop in
department or transit to ward
Are there eDD’s
(first green tick)
(Not part of testing
as IT issues with
link)Yes No
Complete Supply
Column on eDD
Working from TPAR, PODs update
the supply column on the eDD and
refer problems/ discrepancies on
eDD leaving notes via free text
comments
POD Check New
Patients
Using TPAR & PODs assess the
suitability of PODs and
communicate problems /
discrepancies to the ward
pharmacist.
Update POD CHECK on
PharmcyView at bedside
Access to Clinical Portal and
eDD and other IT systems
accessed via intranet
Identify and plan workload for ward 3
• Filter patients with first green tick on eDD column.
•Filter patients with no triage category documented.
•Filter patients due for review today.
Filter
PharmacyView
Are there eDD’s
(first green tick)
(Not part of
testing as IT
issues with link)
Open PharmacyView on desktop
in department or transit to ward
Yes
No
Sign off eDD
(Not part of testing as IT
issues with link)
Filter
PharmacyView
Are there patients
with no triage
category
Yes
NoClinically Review Patients
Med Rec, TPAR screen, Bloods
Update PharmacyView column.
Filter PharmacyView by Review
Date
Review all patients due for
review today.
Access to Clinical Portal and eDD and other IT
systems accessed via intranet
Confirm if new Patient(s) screened from AMU
•Manual examination of medical notes, update Pharmacy View if required
3Minutes+5Minstotransit
toward
Approx20Minutes(Per
Patient)
2Minutes+5Minstotransit
toward
10
Minutes
10 Minutes
20
Minutes
(Per
Ptient)
Approx15
Minutes
(PerPatient)
10Minutes(Per
Patient)
PHARMACY TECHNICIAN
RESULT
New Patient Screening process
only
*Until end of first patient seen
Current practice 60 mins
Testing practice 28 mins
Difference 32
mins
PHARMACIST RESULT
New Patient Screening process
only
*Until end of first patient seen
Current practice 55 mins
Testing practice 37 mins
Difference 18
mins
DischargePatientJourney
Admission
9. PHARMACYVIEW BENEFITS
Captures and displays pharmacy activity
Visible to all members of MDT
No need to transfer this information between
pharmacy teams
Patients requiring a review after initial triage can be
easily identified
Allows more efficient deployment of staff resource –
directed to areas of need rather than on geographical
basis
Opportunity to extract data to display in Qlikview –
everyone will see the same data!
Can be accessed via eWhiteboard screens, PC’s or
mobile devices
Reduces time spent on administrative tasks which can
be re-directed to clinical activities
Staff love it!
10. PHARMACYVIEW WHAT HAPPENS NEXT?
eHealth Team to complete closure report
Currently in use across medical floor Ninewells (12 wards)
Implementation plan will describe process to gain access via IT Portal
and awareness sessions for pharmacy staff
Working with Business Unit to agree specification for measures to be
displayed in Qlikview
Pharmacy View will come as part of the rollout package for the
eWhiteboard
Collaboration with users in other Boards to agree national
specification for system and measures
13. Provides an immediate and real-time view of every patient’s pharmacy service
requirements.
Available throughout the Trust to identify and effectively manage the prescription and
supply of drugs
Supports pharmacists and technicians to record and see, at a glance,
completed/incomplete pharmacy-based requests and alerts
Enabling a more safety-focused approach to the provision of patient care and
eliminating unnecessary patient visits and assessments.
THE PHARMACYVIEW SOLUTION
14. QUESTIONS FOR THE PANEL
Please type in your question in the Go to Webinar panel